Company intelligence / Profile preview
CoreA Therapeutics, Inc.
- Ownership
- Private
- Employees
- ~2
- Development stage
- Preclinical
Overview
CoreA Therapeutics specializes in developing innovative cancer immunotherapies and antibody-drug conjugates targeting solid tumors. Their proprietary platform enables the engineering of NK cells for targeted chemoimmunotherapy. No clinical results are publicly available as of May 2025.
- Therapeutic areas
- Oncology
- Modalities
- Cancer immunotherapies (including NK cell-based therapies)Antibody-drug conjugates (ADCs)
- Industry
- Biotech
Drug pipeline
1 assetBeyond the preview
Go deeper on CoreA Therapeutics, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CoreA Therapeutics, Inc..